Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931382 | 0.91 | PDE4B (0.50) | PDE4BMAPK1RPS6KA1 | |
| SCHEMBL4937069 | 0.90 | PDE4B (0.49) | PDE4BMAPK1RPS6KA1 | |
| SCHEMBL4931722 | 0.89 | PDE4B (0.48) | PDE4BMAPK1RPS6KA1 | |
| SCHEMBL4931730 | 0.87 | PDE4B (0.48) | PDE4BMAPK1RPS6KA1 | |
| SCHEMBL4933954 | 0.85 | PDE4B (0.67) | PDE4B | |
| SCHEMBL4934166 | 0.85 | PDE4B (0.47) | PDE4B | |
| SCHEMBL8281071 | 0.83 | PDE4B (0.62) | PDE4B | |
| SCHEMBL4927800 | 0.83 | PDE4B (0.50) | PDE4B | |
| SCHEMBL4940347 | 0.81 | PDE4B (0.49) | PDE4B | |
| SCHEMBL1363559 | 0.80 | PDE4B (0.60) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | claimed |
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| EP-1751151-A1 | PYRAZOLO '3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005090348-A1 | PYRAZOLO ’3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021058-A1 | Pyrazolo '3,4-B! Pyridine Compounds And Their Use As Phosphodiesterase Type 4(Pde4) Inhibitors | PDE4A, PDE4B, PDE3B | PDE4B 2/4885MAPK1 1547/4885RPS6KA1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.